Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Seres Therapeutics Inc (NQ: MCRB )

7.860 USD +0.430 (+5.79%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 921,579
Open 7.410
Bid (Size) 7.360 (2)
Ask (Size) 8.850 (4)
Prev. Close 7.430
Today's Range 7.310 - 7.860
52wk Range 5.410 - 29.90
Shares Outstanding 91,847,137
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
Tags U/S Financial Market Finance
From AB Newswire
Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host a webcast investor event on Monday, January 31, 2022, from 8:30 a.m. to 10:00 a.m.... 
From Business Wire News Releases

Performance

YTD
-11.09%
-11.09%
1 Month
-9.86%
-9.86%
3 Month
+29.28%
+29.28%
6 Month
+10.70%
+10.70%
1 Year
-67.13%
-67.13%

More News

Read More
New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection
From Business Wire News Releases
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
From Business Wire News Releases
Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis
From Business Wire News Releases
Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection
Tags News Phase 3 Trial General
From Benzinga
Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Ve
From Business Wire News Releases
Seres Posts Interim Microbiome Data Analysis From Failed Ulcerative Colitis Study
Tags Health Care Market News Benzinga
From Benzinga
Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
From Business Wire News Releases
Analysts Predict 15% Upside For The Holdings of VHT
Tags ETFs
From ETF Channel
Interesting MCRB Put And Call Options For December 17th
Tags Stocks
From Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.